Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2019 | Radium-223 in men with bone mCRPC

Daniel George • 2 Jun 2019
ASCO 2019
Genitourinary Cancer Prostate Cancer

Daniel George, MD, of the Duke University Cancer Center, Durham, NC, discusses the use of Radium-223 in the treatment of bone metastatic castrate resistant prostate cancer at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.

More from Daniel George

3:54
Race & prostate cancer: what's the link?
Daniel George • 2 Jun 2019
1:56
Sunitinib for treating high-risk RCC
Daniel George • 2 Jun 2019

Related Videos

4:05
Evaluating triplet therapy in metastatic hormone sensitive prostate cancer
Nick James • 24 Apr 2024
10:42
Management of prostate cancer from the patient perspective
David Matheson • 11 Apr 2024
2:26
Prognostic factors of renal cell cancer in elderly patients
Teemu Murtola • 9 Apr 2024
2:44
The effect of hypoxia on lipid metabolism and prostate cancer tumor growth
Teemu Murtola • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals